December 15, 2015. As members of the Patient, Consumer, and Public Health Coalition, we support FDA’s effort to better characterize drug interactions with hormonal contraceptives since reliable and accurate information is necessary to ensure women’s health. In particular, we recommend clinical evaluation of drug interactions for all drugs that are likely to be used in women of reproductive age and that have the potential to cause birth defects, in addition to improving the quality and usefulness of information in FDA-approved labeling.
Read More »On Health Policy
NCHR Testimony at FDA on Codeine Use in Children
December 10, 2015. NCHR strongly urges the FDA to require labeling that states that codeine is contraindicated for cough and pain in children less than 12 years of age.
Read More »What Would Impact of 21st Century Cures Act be on Your Healthcare Costs and the Lives of Alzheimer’s Patients?
The BMJ, November 23, 2015. A controversial proposed new health law would have had a terrible impact on the lives of Alzheimer’s patients and their families, who would have spent billions on medications that don’t work and can cause cancer.
Read More »Comments on Nondiscrimination in Health Programs and Activities
November 9, 2015. We fully support the Administration’s efforts to “prohibit discrimination on the basis of race, color, national origin, sex, age, or disability in certain health programs and activities.”
Read More »NCHR Testimony at FDA Meeting on Risk Evaluation and Mitigation Strategies (REMS)
October 5, 2015. Our Center strongly supports research and programs to improve drug safety. We remember when REMS were first proposed in legislation, the reason was to enable FDA to approve drugs with serious risks by providing a mechanism to mitigate those risks.
Read More »